| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | RVTY US |
| ISIN code | US7140461093 |
| Industry group | Healthcare |
| Aligned with SDGs |
Revvity is an American healthcare equipment and technology company that serves the diagnostics and life sciences (drug discovery) markets worldwide. It operates through the segments Life Sciences (products and services for life sciences research) and Diagnostics (tools and applications for clinical customers in reproductive health, emerging market diagnostics and applied genomics markets). The company’s customers include academic and research organizations, biotechnology and pharmaceutical companies, doctors, government agencies, laboratories, private health care organisations, and public health authorities.
Investment rationale
Revvity offers several products and services that provide specific solutions to global sustainability challenges. In the clinical area there are prenatal health conditions that in the past could only be detected and diagnosed late in pregnancy when it was difficult to treat (e.g. pre-eclampsia). Revvity is the global market leader in life-saving screening tests for newborns and expectant mothers with its comprehensive portfolio of screening and diagnostic solutions, which save approximately 70 babies every day by detecting over 50 congenital disorders early enough in a pregnancy for physicians to administer necessary treatments for better outcomes.
With its portfolio of detection and imaging solutions, informatics and services, Revvity helps researchers accelerate the discovery-to-commercialisation process, bringing better medicines to market faster. In addition, the company has helped improve healthcare infrastructure in developing countries, for example through donations of diagnostic kits for COVID-19.